Mineralocorticoid Receptor Antagonism Attenuates Cardiac Hypertrophy and Failure in Low-Aldosterone Hypertensive Rats

• Kohzo Nagata

  From the Department of Medical Technology (K.N., A.N., H.K.), Nagoya University School of Health Sciences, Nagoya, Japan; Department of Cardiovascular Genome Science (K.O., J.X., M.Y.), Nagoya University School of Medicine, Nagoya, Japan; Department of Human Functional Genomics (S.I.), Life Science Research Center, Mie University, Tsu, Japan; and Department of Cardiology (T.K., H.I., T.M.), Nagoya University Graduate School of Medicine, Nagoya, Japan.

• Koji Obata

  From the Department of Medical Technology (K.N., A.N., H.K.), Nagoya University School of Health Sciences, Nagoya, Japan; Department of Cardiovascular Genome Science (K.O., J.X., M.Y.), Nagoya University School of Medicine, Nagoya, Japan; Department of Human Functional Genomics (S.I.), Life Science Research Center, Mie University, Tsu, Japan; and Department of Cardiology (T.K., H.I., T.M.), Nagoya University Graduate School of Medicine, Nagoya, Japan.

• Jinglan Xu

  From the Department of Medical Technology (K.N., A.N., H.K.), Nagoya University School of Health Sciences, Nagoya, Japan; Department of Cardiovascular Genome Science (K.O., J.X., M.Y.), Nagoya University School of Medicine, Nagoya, Japan; Department of Human Functional Genomics (S.I.), Life Science Research Center, Mie University, Tsu, Japan; and Department of Cardiology (T.K., H.I., T.M.), Nagoya University Graduate School of Medicine, Nagoya, Japan.

• Sahoko Ichihara

  From the Department of Medical Technology (K.N., A.N., H.K.), Nagoya University School of Health Sciences, Nagoya, Japan; Department of Cardiovascular Genome Science (K.O., J.X., M.Y.), Nagoya University School of Medicine, Nagoya, Japan; Department of Human Functional Genomics (S.I.), Life Science Research Center, Mie University, Tsu, Japan; and Department of Cardiology (T.K., H.I., T.M.), Nagoya University Graduate School of Medicine, Nagoya, Japan.

• Akiko Noda

  From the Department of Medical Technology (K.N., A.N., H.K.), Nagoya University School of Health Sciences, Nagoya, Japan; Department of Cardiovascular Genome Science (K.O., J.X., M.Y.), Nagoya University School of Medicine, Nagoya, Japan; Department of Human Functional Genomics (S.I.), Life Science Research Center, Mie University, Tsu, Japan; and Department of Cardiology (T.K., H.I., T.M.), Nagoya University Graduate School of Medicine, Nagoya, Japan.

• Hirotaka Kimata

  From the Department of Medical Technology (K.N., A.N., H.K.), Nagoya University School of Health Sciences, Nagoya, Japan; Department of Cardiovascular Genome Science (K.O., J.X., M.Y.), Nagoya University School of Medicine, Nagoya, Japan; Department of Human Functional Genomics (S.I.), Life Science Research Center, Mie University, Tsu, Japan; and Department of Cardiology (T.K., H.I., T.M.), Nagoya University Graduate School of Medicine, Nagoya, Japan.

• Tomoko Kato

  From the Department of Medical Technology (K.N., A.N., H.K.), Nagoya University School of Health Sciences, Nagoya, Japan; Department of Cardiovascular Genome Science (K.O., J.X., M.Y.), Nagoya University School of Medicine, Nagoya, Japan; Department of Human Functional Genomics (S.I.), Life Science Research Center, Mie University, Tsu, Japan; and Department of Cardiology (T.K., H.I., T.M.), Nagoya University Graduate School of Medicine, Nagoya, Japan.

• Hideo Izawa

  From the Department of Medical Technology (K.N., A.N., H.K.), Nagoya University School of Health Sciences, Nagoya, Japan; Department of Cardiovascular Genome Science (K.O., J.X., M.Y.), Nagoya University School of Medicine, Nagoya, Japan; Department of Human Functional Genomics (S.I.), Life Science Research Center, Mie University, Tsu, Japan; and Department of Cardiology (T.K., H.I., T.M.), Nagoya University Graduate School of Medicine, Nagoya, Japan.

• Toyoaki Murohara

  From the Department of Medical Technology (K.N., A.N., H.K.), Nagoya University School of Health Sciences, Nagoya, Japan; Department of Cardiovascular Genome Science (K.O., J.X., M.Y.), Nagoya University School of Medicine, Nagoya, Japan; Department of Human Functional Genomics (S.I.), Life Science Research Center, Mie University, Tsu, Japan; and Department of Cardiology (T.K., H.I., T.M.), Nagoya University Graduate School of Medicine, Nagoya, Japan.

• Mitsuhiro Yokota

  From the Department of Medical Technology (K.N., A.N., H.K.), Nagoya University School of Health Sciences, Nagoya, Japan; Department of Cardiovascular Genome Science (K.O., J.X., M.Y.), Nagoya University School of Medicine, Nagoya, Japan; Department of Human Functional Genomics (S.I.), Life Science Research Center, Mie University, Tsu, Japan; and Department of Cardiology (T.K., H.I., T.M.), Nagoya University Graduate School of Medicine, Nagoya, Japan.

抄録

Chronic elevation of plasma aldosterone contributes to heart failure. Mineralocorticoid receptor (MR) antagonism is cardioprotective in such a setting, but whether such protection occurs in the presence of low-aldosterone concentrations remains unclear. We investigated whether MR blockade attenuates cardiac hypertrophy and failure in rats with salt-sensitive hypertension. Dahl salt-sensitive (DS) rats fed a high-salt diet from 7 weeks develop concentric left ventricular (LV) hypertrophy secondary to hypertension at 12 weeks followed by heart failure at 19 weeks (DS-CHF). DS rats on such a diet were treated with a non-antihypertensive dose of the selective MR antagonist eplerenone from 12 to 19 weeks. Renin activity and aldosterone concentration in plasma were decreased in DS-CHF rats compared with controls. LV hypertrophy and fibrosis, as well as macrophage infiltration around coronary vessels, were apparent in DS-CHF rats. The amounts of mRNAs for 11β-hydroxysteroid dehydrogenase type 1, MR, monocyte chemoattractant protein 1, and osteopontin were increased in these hearts. Treatment of DS-CHF rats with eplerenone inhibited these changes in gene expression, as well as coronary vascular inflammation and heart failure. Eplerenone attenuated both the decrease in the ratio of reduced to oxidized glutathione and the increase in NADPH oxidase activity apparent in DS-CHF rat hearts. MR blockade with eplerenone thus resulted in attenuation of LV hypertrophy and failure, without an antihypertensive effect, in rats with low-aldosterone hypertension. The beneficial cardiac effects of eplerenone are likely attributable, at least in part, to attenuation of myocardial oxidative stress and coronary vascular inflammation induced by glucocorticoid-activated MRs.

収録刊行物

• Hypertension

  Hypertension 47 (4), 656-664, 2006-04

  Ovid Technologies (Wolters Kluwer Health)

キーワード

• Internal Medicine

詳細情報

• CRID: 1361137045587473280
• NII論文ID: 30022678437
• DOI: 10.1161/01.hyp.0000203772.78696.67
• ISSN: 15244563
• ISSN: 0194911X
• ISSN: http://id.crossref.org/issn/0194911X
• Web Site: https://www.ahajournals.org/doi/full/10.1161/01.HYP.0000203772.78696.67
• データソース種別:
  • Crossref
  • CiNii Articles
  • KAKEN